A monoclonal antibody (MAb). 4D5. specifically recognising an extracellular epitope of the c-ErbB-2 protein, inhibited the growth of human gastric cancer overexpressing c-ErbB-2 severe combined immunodeficient (SCID) mice. This antibody also reduced the mass of established tumours xenografted into SCID mice, whereas gastric cancer not expressing c-ErbB-2 exhibited no regression in response to 4D5 treatment. In addition, administration of 4D5 prevented colonisation of cancer cells and prolonged the survival of host SCID mice inoculated i.v. with c-ErbB-2-overexpressing tumour cells. This is the first reported study to show that treatment with a single antibody specific to c-ErbB-2 prolongs the survival of host SCID mice bearing xenotransplanted tumours.
amplification and/or overexpression of this gene has been demonstrated in adenocarcinoma of the breast, ovary, lung and stomach (King et al., 1985; Yokota et al., 1986; de Vijver et al., 1987; Slamon et al., 1989; Kern et al., 1990) . Amplification and/or overexpression was found in 8-40% of gastric carcinoma patients and was linked to low survival rates in the patients (Yokota et al.. 1988; Park et al., 1989; Yomemura et al., 1991) . c-ErbB-2 is weakly expressed in normal tissues of adults (De Potter et al., 1989; Press et al., 1990) . From the above findings, the c-ErbB-2 protein is thought to be a good target for antibody therapy of cancers showing overexpression. Several series of MAbs recognising the extracellular domain of the c-ErbB-2 protein have been tested for their anti-human tumour effects, mainly in vitro, and were found to produce inhibitory effects on cancer cell lines overexpressing c-ErbB-2 (Drebin et al., 1985; Hudziak et al., 1989; Hancock et al., 1991; Stancovski et al., 1991; Tagliabue et al., 1991; Harwerth et al., 1992; Kasprzyk et al., 1992) . Only a few reports of the in vivo effects of MAbs on tumours expressing the c-erbB-2 product have been published. Stancovski et al., (1991) reported somewhat conflicting results on the in vivo effects of these MAbs on proliferation of murine fibroblasts transfected with the cerbB-2 gene. Only Kasprzyk et al.,. (1992) (Fendly et al., 1990) as well as reduction of pl85 2 phosphorylation (Kumar et al., 1991) . To study the in vivo effects of MAb 4D5 directed against the c-ErbB-2 protein on human tumour regression and host survival, the extent of tumour mass reduction and survival rate were detemined in treated vs untreated mice bearing gastnc cancer overexpressing c-ErbB-2.
Materials and methods

Animals
Balb/cA-nu mice were obtained from CLEA Japan Inc (Tokyo, Japan). C.B-17-scid mice were a gift from Dr GC Bosma (Fox Chase Cancer Center, Philadelphia, PA, USA) and bred in our animal quarters. The mice were used at 6-8 weeks of age in accordance with the animal care guidelines of the Central Institute for Experimental Animals (CIEA), including animal anaesthesia procedures. We performed periodic microbiological monitoring to confirm that the mice were kept under specific pathogen-free conditions during the experiment. 4 and 7 or 7, 10 and 13. Survival periods of mice were observed for 180 days. When the animals showed severe wasting and were apparently moribund owing to tumour growth in the lung, the animals were not observed further and the day of sacrifice was recorded according to the UKC-CCR guidelines (Workman et al., 1988) . Surviving animals were sacrificed at the end of the experiment and sectioned for microscopic examination of tumour foci. In a preliminary experiment, mice inolculated with 1 x 106 4-1ST cells were sacified on day 50 to confirm the presence of tumour foci in the lung.
Resols
Expression of c-ErbB-2 product in hwnan gastric carcinoma xenografts, 4-IST and St-15
To selet a suitable human tumour line as an in vivo model for therapy using anti-c-ErbB-2 MAb, we first screened the immunoreactivity with an anti-c-ErbB-2 polyclonal antibody of 18 human gastric carcnomas xenotransplanted into nude mice by immunoblotting (data not shown). Among these tumours, the 4-1ST tumour lne derived from a poorly differentiated adenocarcnoma revealed a clear band at a moklular mass of 185 kDa, the reported molecular mass of p185'2, whereas St-15 showed no reactive product (Figure 1 ). 4-1ST also showed many bands with a lower molcular mass than 185 kDa. We assume that these lower bands were caused by reaction with the degraded c-ErbB-2 product, since the xenografted tumours contained necrotic tissue in their centre. An anti-phosphotyrosine antibody, 5E3, reacted with a 185 kDa protein immunoprecipitated from the 4-1ST tumour lysate with 4D5, suggesting that pl852 overexpressed in this tumour is phosphorylated (Figure 1 ). Northern blot analysis showed that the kvels of c-ErbB-2 gene expression in tumour 4-1ST but not St-15 were similar to those in the SKBR-3 breast cancer cell line (Figure 2 ). Effects of4D5 on exponentially growing tumors ui SCID mice To examine whether injection of 4D5 caused regression of establishd tumours, an experiment was performed after the tumours had been allowed to grow measurably. When 4-1ST tumour-bearing animals were treated with a single administration of 4D5 (36mg kg-'), tumour mass reduction was obsved 10 days after adminisraton, although complete regression was not observed (Figure 3a) . Animals given intermittent administration of 4D5 (12 mg (1988) also demonstrated macrophage-mediated cytotoxicity in the suppression of human carcinoma growth in nude mice by administration of MAbs directed against human colon carcinoma.
Whatever the mechanism involved, our results showing that MAb 4D5 was able to eliminate tumour cells from mice bearing human gastnrc cancer and to rescue them from cancer death suggest that the use of 4D5 as an adjuvant after surgical resection might be effective for elimination of minimal residual human gastric cancers overexpressing cErbB-2 protein which respond poorly to currently available systemic chemotherapies and are associated with poor prognosis.
